AKT1 and hepatocellular carcinoma: These findings suggest that TMCO3 serves as a useful biomarker in HCC, and targeting TMCO3 may provide a potential therapeutic strategy for HCC, especially in HCC patients with a highly activated PI3K/AKT pathway.